brand logo

Am Fam Physician. 2004;70(9):1767

Clinical Question: Does treatment for lead exposure affect neurologic development in children?

Setting: Population-based

Study Design: Randomized controlled trial (double-blinded)

Synopsis: The authors enrolled 780 children, 12 to 33 months of age, with a blood lead level between 20 and 44 mcg per dL (0.97 to 2.12 μmol per L). After the level of lead was confirmed, the children were randomized to receive placebo or succimer in a dosage of 1,050 mg per m2 per day for seven days, and then 700 mg per m2 per day for 19 additional days. Two weeks after the completion of therapy, the children who still had elevated blood lead levels were treated for up to two more courses. The homes of all of the children were cleaned, and paint was stabilized as necessary to prevent continued lead exposure. Children were evaluated three years after treatment and again at seven years of age using the Developmental Neuropsychological Assessment, the Wechsler Scales of Intelligence, the Conners’ Parent Rating Scale–Revised, and other tests.

Six months after treatment, blood lead levels were an average 4.5 mcg per dL (0.22 μmol per L) lower in the treated group; 12 months after treatment, blood lead levels were 2.7 mcg per dL (0.13 μmol per L) lower. By the time the children reached seven years of age, the blood levels were similar in both groups (8.0 mcg per dL [0.39 μmol per L]), with a similar proportion of children in both groups having a blood lead concentration greater than 10 mcg per dL (0.48 μmol per L). However, in the 83 percent of children evaluated at seven years of age, no difference was noted between the groups on any of the 12 neuropsychologic outcomes, which is concordant with other findings three years after treatment (Liu X, et al. Do children with falling blood lead levels have improved cognition? Pediatrics October 2002;110:787–91).

Bottom Line: Among children with elevated blood lead levels, drug treatment reduces those levels, although the children’s intelligence, cognition, and other neurodevelopment markers are the same at seven years of age as those of children whose homes were made free of lead but who did not receive medication. These findings support guidelines that do not recommend chelation therapy in children with blood lead levels of less than 45 mcg per dL (2.17 μmol per L; United States Centers for Disease Control and Prevention Guidelines, 2002). (Level of Evidence: 1b)

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Continue Reading


More in AFP

Copyright © 2004 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.